{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:41:47Z","timestamp":1792456907155,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the long-term safety and potential neuroprotective effects of human fetal neural precursor cell transplantation in individuals with progressive multiple sclerosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study assessed long-term follow-up data (median 5.7 years) from participants in a first-in-human phase I trial (NCT03269071) investigating neural cell transplantation in progressive multiple sclerosis. Clinical and radiological available data were collected and compared to baseline values and reference populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Long-term follow-up data were available for 11 of 12 patients. No serious adverse events related to cell transplantation occurred, confirming long-term safety. Although physical disability progressed over time, cognition remained stable compared to baseline. Five patients developed new T2-hyperintense brain lesions without associated contrast enhancement. Long-term gray matter atrophy rates were lower than those observed during the initial two years post-transplantation. Rates of gray and white matter atrophy approximated those of age-matched healthy individuals and patients with early-stage multiple sclerosis, with a trend for a lower atrophy rate compared to a control cohort with progressive disease. These structural findings were consistent with stable levels of circulating biomarkers of neurodegeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings support the long-term safety of fetal neural cell transplantation in progressive multiple sclerosis. Although exploratory in nature, the stability of cognitive function, reduced brain atrophy, and consistent biomarker profiles support the hypothesis of a possible neuroprotective effect that warrants further investigation in a controlled clinical trial setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-026-05148-5","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:35:29Z","timestamp":1784702129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neural stem cell transplantation in progressive multiple sclerosis: STEMS study long-term outcomes"],"prefix":"10.1186","volume":"17","author":[{"given":"Maria A.","family":"Rocca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Genchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Azzimonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gattuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Storelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vezzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Falini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianvito","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"3","key":"5148_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology"},{"issue":"11","key":"5148_CR2","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1172\/JCI92387","volume":"127","author":"D De Feo","year":"2017","unstructured":"De Feo D, Merlini A, Brambilla E, Ottoboni L, Laterza C, Menon R, et al. Neural precursor cell-secreted TGF-beta2 redirects inflammatory monocyte-derived cells in CNS autoimmunity. J Clin Invest. 2017;127(11):3937\u201353.","journal-title":"J Clin Invest"},{"issue":"8","key":"5148_CR3","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/nn.3163","volume":"15","author":"Z Kokaia","year":"2012","unstructured":"Kokaia Z, Martino G, Schwartz M, Lindvall O. Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat Neurosci. 2012;15(8):1078\u201387.","journal-title":"Nat Neurosci"},{"issue":"3","key":"5148_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ana.21745","volume":"66","author":"S Pluchino","year":"2009","unstructured":"Pluchino S, Gritti A, Blezer E, Amadio S, Brambilla E, Borsellino G, et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann Neurol. 2009;66(3):343\u201354.","journal-title":"Ann Neurol"},{"issue":"6933","key":"5148_CR5","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nature01552","volume":"422","author":"S Pluchino","year":"2003","unstructured":"Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature. 2003;422(6933):688\u201394.","journal-title":"Nature"},{"issue":"7048","key":"5148_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nature03889","volume":"436","author":"S Pluchino","year":"2005","unstructured":"Pluchino S, Zanotti L, Rossi B, Brambilla E, Ottoboni L, Salani G, et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature. 2005;436(7048):266\u201371.","journal-title":"Nature"},{"key":"5148_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fnins.2014.00092","volume":"8","author":"E Butti","year":"2014","unstructured":"Butti E, Cusimano M, Bacigaluppi M, Martino G. Neurogenic and non-neurogenic functions of endogenous neural stem cells. Front Neurosci. 2014;8:92.","journal-title":"Front Neurosci"},{"issue":"1","key":"5148_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41591-022-02097-3","volume":"29","author":"A Genchi","year":"2023","unstructured":"Genchi A, Brambilla E, Sangalli F, Radaelli M, Bacigaluppi M, Furlan R, et al. Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study. Nat Med. 2023;29(1):75\u201385.","journal-title":"Nat Med"},{"issue":"12","key":"5148_CR9","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.stem.2023.11.001","volume":"30","author":"MA Leone","year":"2023","unstructured":"Leone MA, Gelati M, Profico DC, Gobbi C, Pravata E, Copetti M, et al. Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive multiple sclerosis. Cell Stem Cell. 2023;30(12):1597\u2013609. e8.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"5148_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13287-024-04096-2","volume":"16","author":"S Jiang","year":"2025","unstructured":"Jiang S, Bao X, Zhong C, Wang R. Mapping the global clinical landscape of stem cell therapies for neurological diseases from 1998 to 2023: an analysis based on the Trialtrove database. Stem Cell Res Ther. 2025;16(1):41.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"5148_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292\u2013302.","journal-title":"Ann Neurol"},{"issue":"11","key":"5148_CR12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352.","journal-title":"Neurology"},{"issue":"4","key":"5148_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1017\/S1355617706060723","volume":"12","author":"RH Benedict","year":"2006","unstructured":"Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006;12(4):549\u201358.","journal-title":"J Int Neuropsychol Soc"},{"issue":"13","key":"5148_CR14","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1177\/1352458518808204","volume":"25","author":"L Strober","year":"2019","unstructured":"Strober L, DeLuca J, Benedict RH, Jacobs A, Cohen JA, Chiaravalloti N, et al. Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis. Mult Scler. 2019;25(13):1781\u201390.","journal-title":"Mult Scler"},{"key":"5148_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.neuroimage.2017.04.034","volume":"155","author":"S Valverde","year":"2017","unstructured":"Valverde S, Cabezas M, Roura E, Gonzalez-Villa S, Pareto D, Vilanova JC, et al. Improving automated multiple sclerosis lesion segmentation with a cascaded 3D convolutional neural network approach. NeuroImage. 2017;155:159\u201368.","journal-title":"NeuroImage"},{"issue":"1","key":"5148_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1006\/nimg.2002.1040","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage. 2002;17(1):479\u201389.","journal-title":"NeuroImage"},{"issue":"9","key":"5148_CR17","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1002\/hbm.21344","volume":"33","author":"M Battaglini","year":"2012","unstructured":"Battaglini M, Jenkinson M, De Stefano N. Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp. 2012;33(9):2062\u201371.","journal-title":"Hum Brain Mapp"},{"key":"5148_CR18","first-page":"197","volume":"6","author":"J Ashburner","year":"2012","unstructured":"Ashburner J, Ridgway GR. Symmetric diffeomorphic modeling of longitudinal structural MRI. Front Neurosci. 2012;6:197.","journal-title":"Front Neurosci"},{"issue":"2","key":"5148_CR19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1148\/radiol.2018172468","volume":"288","author":"L Storelli","year":"2018","unstructured":"Storelli L, Rocca MA, Pagani E, Van Hecke W, Horsfield MA, De Stefano N, et al. Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging. Radiology. 2018;288(2):554\u201364.","journal-title":"Radiology"},{"issue":"13","key":"5148_CR20","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"5148_CR21","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"5148_CR22","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","volume":"19","author":"RHB Benedict","year":"2020","unstructured":"Benedict RHB, Amato MP, DeLuca J, Geurts JJG. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020;19(10):860\u201371.","journal-title":"Lancet Neurol"},{"issue":"3","key":"5148_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier S, Willemse EAJ, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, et al. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurol. 2023;80(3):287\u201397.","journal-title":"JAMA Neurol"},{"key":"5148_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2023.04.014","volume":"129","author":"ET Smith","year":"2023","unstructured":"Smith ET, Hennessee JP, Wig GS, Frank S, Gonzalez H, Bacci J, et al. Longitudinal changes in gray matter correspond to changes in cognition across the lifespan: implications for theories of cognition. Neurobiol Aging. 2023;129:1\u201314.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"5148_CR25","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1007\/s00415-023-11778-z","volume":"270","author":"M Azzimonti","year":"2023","unstructured":"Azzimonti M, Preziosa P, Pagani E, Valsasina P, Tedone N, Vizzino C, et al. Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study. J Neurol. 2023;270(9):4296\u2013308.","journal-title":"J Neurol"},{"issue":"3","key":"5148_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1352458517751650","volume":"25","author":"CM Rimkus","year":"2019","unstructured":"Rimkus CM, Schoonheim MM, Steenwijk MD, Vrenken H, Eijlers AJ, Killestein J, et al. Gray matter networks and cognitive impairment in multiple sclerosis. Mult Scler. 2019;25(3):382\u201391.","journal-title":"Mult Scler"},{"issue":"9","key":"5148_CR27","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1177\/1352458511404916","volume":"17","author":"SD Roosendaal","year":"2011","unstructured":"Roosendaal SD, Bendfeldt K, Vrenken H, Polman CH, Borgwardt S, Radue EW, et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler. 2011;17(9):1098\u2013106.","journal-title":"Mult Scler"},{"issue":"3","key":"5148_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/ana.21436","volume":"64","author":"E Fisher","year":"2008","unstructured":"Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008;64(3):255\u201365.","journal-title":"Ann Neurol"},{"issue":"5816","key":"5148_CR29","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1126\/science.1136281","volume":"315","author":"MA Curtis","year":"2007","unstructured":"Curtis MA, Kam M, Nannmark U, Anderson MF, Axell MZ, Wikkelso C, et al. Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science. 2007;315(5816):1243\u20139.","journal-title":"Science"},{"issue":"3","key":"5148_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/cne.20798","volume":"494","author":"A Quinones-Hinojosa","year":"2006","unstructured":"Quinones-Hinojosa A, Sanai N, Soriano-Navarro M, Gonzalez-Perez O, Mirzadeh Z, Gil-Perotin S, et al. Cellular composition and cytoarchitecture of the adult human subventricular zone: a niche of neural stem cells. J Comp Neurol. 2006;494(3):415\u201334.","journal-title":"J Comp Neurol"},{"issue":"6976","key":"5148_CR31","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nature02301","volume":"427","author":"N Sanai","year":"2004","unstructured":"Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S, et al. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature. 2004;427(6976):740\u20134.","journal-title":"Nature"},{"issue":"1","key":"5148_CR32","doi-asserted-by":"publisher","first-page":"7579","DOI":"10.1038\/s41467-022-35341-y","volume":"13","author":"E Butti","year":"2022","unstructured":"Butti E, Cattaneo S, Bacigaluppi M, Cambiaghi M, Scotti GM, Brambilla E, et al. Neural precursor cells tune striatal connectivity through the release of IGFBPL1. Nat Commun. 2022;13(1):7579.","journal-title":"Nat Commun"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05148-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05148-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05148-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:27:23Z","timestamp":1792456043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05148-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5148"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05148-5","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Neural Stem Cell Transplantation in Multiple Sclerosis Patient: a Phase I Study was approved by IRCCS Ospedale San Raffaele ethics committee and authorized by the Italian Medicines Agency (AIFA\/SC\/P\/28404) on 20 march 2017. All participants provided written consent to participate. Long-term follow up (LT-FU) data have been collected according to EMA Guideline on safety and efficacy follow-up and risk management of Advanced Therapy Medicinal Products (EMEA\/149995\/2008 rev.1).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. G. Martino is Editor of Stem Cell Research & Therapy. The authors declare that they have no other potential conflicts of interest. This is a non-profit study, and none of the authors have any commercial relationships with companies whose products are used in this study or could be affected by its outcomes.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"371"}}